Company Profile
Ibio Inc Stock Price, News & Analysis
- Ticker:
- IBIO
- Exchange:
- AMEX
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.39 USD (-0.71%)
Close
Last updated: August 6, 2026
87.4M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IBIO closed down 0.71% at $1.39. No new same-company headline was identified in the current news window.
Company overview
AI-Enabled Antibody Discovery
iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties.
IBIO-600
IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment.
Cardiopulmonary Expansion
The pipeline also includes a bispecific antibody program for pulmonary hypertension associated with heart failure with preserved ejection fraction.
Future catalysts
iBio has received Australian regulatory clearance to initiate a first-in-human Phase 1 study of IBIO-600.
Recent news
- 01
- 02
- 03
iBio to Participate in Upcoming Healthcare Investor Conferences
Source: Ibio Inc
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ibio Inc (IBIO)?
Ibio Inc (IBIO) most recently closed at 1.39 USD, a -0.71% move versus the previous session.
What is the market cap of Ibio Inc (IBIO)?
Ibio Inc currently has a market capitalization of 87.4M USD on BioPharmSignal.
What does Ibio Inc do?
AI-Enabled Antibody Discovery iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties. IBIO-600 IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment. Cardiopulmonary Expansion The pipeline...
On which exchange is IBIO stock listed?
Ibio Inc (IBIO) is associated with AMEX, United States, Biopharma.
What is IBIO-600?
iBio has received Australian regulatory clearance to initiate a first-in-human Phase 1 study of IBIO-600.
Which conditions is Ibio Inc targeting with IBIO-600?
Ibio Inc is associated with obesity based on its company overview and current catalyst commentary.
How does Ibio Inc describe recent progress with IBIO-600?
iBio has received Australian regulatory clearance to initiate a first-in-human Phase 1 study of IBIO-600.
What is AI-Enabled?
AI-Enabled Antibody Discovery iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties.